NASDAQ: GLUEMonte Rosa Therapeutics Inc Stock
$14.07-0.25 (-1.75%)
Updated Sep 11, 2026
GLUE Price
$14.07
Fair Value Price
$24.35
Market Cap
$1.20B
52 Week Low
$6.06
52 Week High
$25.77
P/E
-7.99x
P/B
2.46x
P/S
85.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.73M
Earnings
-$161.12M
Gross Margin
100%
Operating Margin
-570.8%
Profit Margin
-560.9%
Debt to Equity
0.42
Operating Cash Flow
-$24M
Beta
1.62
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GLUE Overview
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company developing of novel small molecule precision medicines that use the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways. Monte Rosa Therapeutics was incorporated in 2019 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLUE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GLUE
Ranked#252 of 459
Ranked#252 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.12 | A | |
| $6.85 | A | |
| $41.52 | A |
Be the first to know about important GLUE news, forecast changes, insider trades & much more!
GLUE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLUE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLUE ($14.07) is undervalued by 42.23% relative to our estimate of its Fair Value price of $24.35 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GLUE ($14.07) is significantly undervalued by 42.23% relative to our estimate of its Fair Value price of $24.35 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLUE due diligence checks available for Premium users.
Valuation
GLUE fair value
Fair Value of GLUE stock based on Discounted Cash Flow (DCF)
Price
$14.07
Fair Value
$24.35
Undervalued by
42.23%
GLUE ($14.07) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLUE ($14.07) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLUE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GLUE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.99x
Industry
8.81x
Market
40.27x
GLUE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.46x
Industry
5.32x
GLUE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLUE's financial health
Profit margin
Revenue
$9.0M
Net Income
-$43.4M
Profit Margin
-483.9%
GLUE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GLUE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$691.2M
Liabilities
$203.9M
Debt to equity
0.42
GLUE's short-term assets ($631.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLUE's short-term assets ($631.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLUE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GLUE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$44.1M
Investing
-$28.9M
Financing
$3.2M
GLUE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLUE vs Biotech Stocks
Monte Rosa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.